HC Wainwright Forecasts Strong Price Appreciation for Inozyme Pharma (NASDAQ:INZY) Stock

Inozyme Pharma (NASDAQ:INZY) had its target price boosted by HC Wainwright from $14.00 to $16.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Inozyme Pharma’s Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

Several other research firms have also recently weighed in on INZY. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Stifel Nicolaus assumed coverage on Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target for the company. Raymond James assumed coverage on Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target (down previously from $15.00) on shares of Inozyme Pharma in a report on Tuesday, November 5th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma has an average rating of “Buy” and an average price target of $17.25.

Inozyme Pharma Price Performance

NASDAQ INZY opened at $2.00 on Friday. Inozyme Pharma has a twelve month low of $1.97 and a twelve month high of $7.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The stock has a market capitalization of $128.48 million, a PE ratio of -1.28 and a beta of 1.35. The stock has a 50-day simple moving average of $3.02 and a 200 day simple moving average of $4.38.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. Research analysts anticipate that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Investors Weigh In On Inozyme Pharma

Several large investors have recently modified their holdings of INZY. Deerfield Management Company L.P. Series C bought a new stake in Inozyme Pharma during the 2nd quarter worth approximately $52,000. Virtu Financial LLC bought a new stake in Inozyme Pharma during the 3rd quarter worth approximately $64,000. Meeder Asset Management Inc. bought a new stake in Inozyme Pharma during the 2nd quarter worth approximately $68,000. SG Americas Securities LLC bought a new stake in Inozyme Pharma during the 3rd quarter worth approximately $81,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Inozyme Pharma during the 2nd quarter worth approximately $84,000. 88.30% of the stock is currently owned by institutional investors.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.